TyRx new ICD features target surgical site infections
TyRx, a provider of convergent drug-device medical products, has launched its Aigisrx ICD, an anti-bacterial envelope designed to stabilize the implanted device and help provide protection against surgical site infections (SSI) associated with implantable cardioverter defibrillators (ICDs).
The launch of Aigisrx ICD extends TyRx's Aigisrx cardiac rhythm management device (CRMD) platform to the ICD market, according to the company. The Aigisrx CRMD platform also includes Aigisrx PM, the company's anti-bacterial coated mesh designed specifically for implanted pacemakers. TyRx received FDA 510(k) clearance of Aigisrx CRMD in January.
During a CRMD implantation procedure, the Monmouth Junction, N.J.-based TyRx said physicians insert the pacemaker or ICD into the Aigisrx anti-bacterial envelope and positions the device within the surgically created pocket. Once implanted, Aigisrx provides an adjunct to general antibiotic therapy by eluting the antimicrobial agents rifampin and minocycline and serves to stabilize the implanted pacemaker or defibrillator.
The launch of Aigisrx ICD extends TyRx's Aigisrx cardiac rhythm management device (CRMD) platform to the ICD market, according to the company. The Aigisrx CRMD platform also includes Aigisrx PM, the company's anti-bacterial coated mesh designed specifically for implanted pacemakers. TyRx received FDA 510(k) clearance of Aigisrx CRMD in January.
During a CRMD implantation procedure, the Monmouth Junction, N.J.-based TyRx said physicians insert the pacemaker or ICD into the Aigisrx anti-bacterial envelope and positions the device within the surgically created pocket. Once implanted, Aigisrx provides an adjunct to general antibiotic therapy by eluting the antimicrobial agents rifampin and minocycline and serves to stabilize the implanted pacemaker or defibrillator.